Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Local newcomer aims to break into Nordic generic market dominated by multinationals

This article was originally published in Scrip

Executive Summary

A company that has set itself the target of becoming the fifth largest generics player in the Nordic region by 2015 has launched its first two products. Norwegian firm Navamedic, which last year signed a deal with the major generics producer Aspen of South Africa giving it exclusive rights to sell Aspen products in the Nordic and Benelux markets, has launched the immunosuppressant mycophenolate mofetil in Sweden, Denmark and Finland, and the antipsychotic olanzapine in Finland and the Netherlands.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC014797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel